As CBD and medical-grade cannabis continue gaining ground in the pharmaceutical and wellbeing sectors, policymakers, scientific researchers, case studies and reliable resources regularly report on the many benefits of both CBD and medicinal cannabis.
Considered a natural approach to supporting health, both CBD and medical cannabis are distinct preparations originating from the Cannabis sativa plant. Medical cannabis describes pharmaceutical products derived either synthetically or directly from the compounds found within the cannabis plant. Whereas CBD products generally contain other cannabis compounds, including hemp, terpenes and flavonoids.
The main differences between these plant-based therapeutics are the benefits, uses and effects, and the governance surrounding them. Over-the-counter CBD products are regarded as food supplements and cannot legally contain more than trace amounts of tetrahydrocannabinol (THC). THC is more commonly associated with the psychoactive high, intoxication or sense of euphoria that users report when smoking or ingesting marijuana.
Pioneering Treatments for Severe and Chronic Pain
Medicinal cannabis is available from the NHS on prescription and is authorised for patient use by a specialist doctor. Whilst medical cannabis is used under the supervision of a medical professional to relieve symptoms and treat conditions, CBD is primarily used to reduce pain and promote relaxation.
As with all medication natural or otherwise, individual biochemistry leaves room for side effects which can include dizziness, fatigue, dry mouth, light-headedness, drowsiness and nausea. Equally, it has interactions with and can alter the effects of other prescribed medications. Although a significant part of the allure is eliminating the need for addictive and sedating prescription painkillers such as opioids and NSAIDs.
Associated Benefits
Renowned for its antioxidant and anti-inflammatory benefits and for supporting the immune system, the health benefits associated with medicinal cannabis include treating severe and chronic pain and cover a variety of diseases, illnesses and even life-limiting conditions including:
- Cancer-related pain and offsetting side effects from chemotherapy
- Alzheimer's, Parkinson’s and Crohn's disease
- Arthritis and neuropathic pain
- Epilepsy, multiple sclerosis, fibromyalgia and muscle spasms
- Anxiety, depression and insomnia
- Preventing inflammatory responses that may result in disease
An Economic Model for Supply and Demand
Considering all of this and in the face of a global shift towards legalisation and accelerated demand, boutique investment partnership Orange River Wealth has identified the medicinal cannabis market as one with immense potential.
The major component to an estimated $104 Billion USD market by 2024, medicinal cannabis represents a burgeoning investment opportunity. Based in London’s Mayfair and via its wholly owned subsidiary Orange River Capital, Orange River Wealth has reached an agreement to purchase 49% of an operational medicinal cannabis facility in South Africa.
This facility has exclusive rights as a fully licensed pharmaceutical cannabis cultivator and producer, affording global brand potential and considerable operational expansion. With a projected valuation of over $150 Million USD, Orange River Wealth is now offering qualifying investors the opportunity to participate in this best-in-class, exponential growth investment opportunity.
To find out more, please contact +44 (0) 207 769 6722 or visit https://orangeriverwealth.com/
